VA/DoD obesity guideline discourages stopping effective GLP-1 weight-loss drugs
A federal guideline update tells VA and Defense clinicians not to stop obesity medication that is working, and not to require a lifestyle program first.
The Department of Veterans Affairs and the Department of Defense now advise against stopping an obesity medication that is working, as part of a 2025 update to their clinical practice guideline for adult overweight and obesity management. A synopsis of the guideline was published in Annals of Internal Medicine [1][2].
The update replaces the 2020 version. A multidisciplinary panel of VA and DoD clinicians wrote 12 key questions, and an independent third party, Sigma Health Consulting, reviewed evidence published from April 1, 2019, through January 6, 2025. Recommendations were graded using the GRADE approach, which weighs evidence quality, benefits and harms, patient values gathered in focus groups, and factors such as resources and feasibility. The result was 23 clinical recommendations: 8 new, 4 reviewed and replaced, 7 reviewed and amended, and 4 carried forward unchanged [2]. Work group members reported no financial conflicts of interest [2].
On medications, the panel wrote that there was insufficient evidence to recommend for or against delaying pharmacotherapy while a patient tries lifestyle intervention, and it set no requirement to complete a comprehensive lifestyle intervention before starting other treatments [1][2]. The guideline supports flexible, individualized integration of medication and lifestyle programs and discourages discontinuation of effective medications to prevent weight regain [1][2]. The synopsis says new and updated recommendations address medications containing glucagon-like peptide-1 receptor agonists, along with endoscopic therapies and metabolic and bariatric surgery [1][2]. It does not name specific products in the text available, and the pharmacotherapy rows of the recommendation table were not included there, so which specific drugs the new recommendations cover has not been disclosed [1][2].
The guideline recommends routine screening for overweight and obesity in all adults using a body mass index of 25 kg/m2 or higher, or 23 kg/m2 or higher for Asian adults, along with waist circumference and clinical context to refine risk [1][2]. Comprehensive lifestyle intervention, which always includes behavioral, dietary, and physical activity components, remains a strong recommendation as the foundation of care [2]. Other recommendations, all rated weak for, include cognitive behavioral interventions for people experiencing internalized weight bias and stigma; intragastric balloons with a lifestyle program for patients with a BMI of 30 kg/m2 or higher; metabolic and bariatric surgery with a lifestyle program for patients with a BMI of 30 kg/m2 or higher and type 2 diabetes, or a BMI of 35 kg/m2 or higher; and endoscopic sleeve gastroplasty with a lifestyle program for patients with a BMI of 30 kg/m2 or higher [2].
The synopsis frames the stakes in numbers. Obesity affects 40% of U.S. adults and is projected to affect 1 in 2 adults by 2030 [2]. Among active-duty service members, obesity prevalence rose from 10.4% in 2012 to 21.6% in 2022, and 68% had a BMI in the overweight or obesity category [2]. Among veterans receiving VA care, overweight and obesity rates exceed those in the general population, and most veterans enrolled in VA care gain significant weight within 10 years of separating from service [2]. The guideline describes obesity as a chronic, relapsing neurohormonal disease associated with more than 200 health conditions [1][2].
Why it matters for patients
The clearest practical change is the guidance on continuing treatment. For patients in the VA or military health system who are losing weight on a medication, the guideline language discourages stopping it simply to avoid regain, and it does not require finishing a lifestyle program before medication can start [1][2]. That removes a step some patients have been asked to complete first.
The screening thresholds also matter. The guideline keeps a lower BMI cutoff of 23 kg/m2 for Asian adults, alongside the 25 kg/m2 cutoff for other adults, and calls for waist circumference and clinical context to be considered together rather than BMI alone [1][2].
The synopsis does not address cost, insurance coverage, or supply, and it does not say how VA or DoD pharmacies will handle prescriptions for these medications. Those details have not been reported [1][2].
What happens next
The full guideline, including Appendixes A, C, and F, is published by the VA at healthquality.va.gov/guidelines/CD/obesity [2]. No timeline for putting the 2025 recommendations into VA or DoD practice has been disclosed in the synopsis, and it is not yet known whether other health systems or insurers will adopt the same language [1][2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.